R Veillon
Overview
Explore the profile of R Veillon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
640
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wislez M, Mascaux C, Cadranel J, Thomas Q, Ricordel C, Swalduz A, et al.
Eur J Cancer
. 2025 Feb;
219:115301.
PMID: 39970524
Introduction: Sotorasib has shown efficacy in a phase 3 trial compared to docetaxel among previously treated non-small cell lung cancer (NSCLC) patients with a KRAS G12C mutation. However, its real-world...
2.
Pons-Tostivint E, Hulo P, Guardiolle V, Bodot L, Rabeau A, Porte M, et al.
Cancer Immunol Immunother
. 2023 Feb;
72(6):1891-1892.
PMID: 36847863
No abstract available.
3.
Pons-Tostivint E, Hulo P, Guardiolle V, Bodot L, Rabeau A, Porte M, et al.
Cancer Immunol Immunother
. 2023 Jan;
72(6):1881-1890.
PMID: 36690799
Introduction: Pembrolizumab alone (IO-mono) or in combination with platinum-based chemotherapy (CT-IO) is first-line standard of care for advanced non-small cell lung cancer (NSCLC) patients with PD-L1 ≥ 50%. This retrospective...
4.
Gefard-Gontier E, Markich R, Zysman M, Veillon R, Daste A, Domblides C, et al.
Cancer Immunol Immunother
. 2022 Mar;
71(11):2609-2618.
PMID: 35305123
Background: To investigate the evolution of bone metastases in patients receiving immune checkpoint inhibitors (ICI). Methods: A single-center retrospective study included cancer patients with bone metastases treated with ICI at...
5.
Lefebvre C, Martin E, Hendriks L, Veillon R, Puisset F, Mezquita L, et al.
Respir Med Res
. 2020 Sep;
78:100788.
PMID: 32980653
Purpose: Anti Programmed Death-ligand (PD1/PD-L1) directed immune-checkpoint-inhibitors (ICI) are widely used to treat patients with advanced non-small cell lung cancer (NSCLC) who progress after first line chemotherapy. The best strategy...
6.
Rouviere D, Veillon R, Chaltiel L, Simonneau Y, Filleron T, Milia J, et al.
Rev Mal Respir
. 2019 Jun;
36(5):583-590.
PMID: 31202602
The central nervous system (CNS), through carcinomatous meningitis or solid brain metastases, is the most common site of recurrence in non-small cell lung cancers (NSCLC) with activating mutations. Our retrospective...
7.
Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot A, Mezquita L, et al.
Ann Oncol
. 2019 May;
30(8):1321-1328.
PMID: 31125062
Background: Anti-PD1/PD-L1 directed immune checkpoint inhibitors (ICI) are widely used to treat patients with advanced non-small-cell lung cancer (NSCLC). The activity of ICI across NSCLC harboring oncogenic alterations is poorly...
8.
Chan H, Paya C, Andrebe C, Veillon R, Pechmeja J, Mercier A, et al.
J Fr Ophtalmol
. 2017 Mar;
39(10):e275-e277.
PMID: 28340934
No abstract available.
9.
De Beer T, Wiggenhorn M, Veillon R, Debacq C, Mayeresse Y, Moreau B, et al.
Anal Chem
. 2009 Aug;
81(18):7639-49.
PMID: 19681620
The aim of the present paper is to demonstrate the importance of using complementary process analyzers (PAT tools) for the process monitoring, analysis, and understanding of freeze drying. A mannitol...
10.
Mayeresse Y, Veillon R, Sibille P, Nomine C
PDA J Pharm Sci Technol
. 2007 Aug;
61(3):160-74.
PMID: 17722483
A cold plasma ionization device has been designed to monitor freeze-drying processes in situ by monitoring lyophilization chamber moisture content. This plasma device, which consists of a probe that can...